Generex subsidiary, Immune Tolerance Network to develop improved diabetes diagnostic test

WORCESTER, Mass. The Immune Tolerance Network and a company that develops immunotherapeutics have signed an agreement to implement a better diagnostic test for Type 1 diabetes.

Antigen Express, a subsidiary of Generex Biotechnology Corp., said Tuesday that the diagnostic test is based on technology that Antigen Express is developing and that the ability to identify patients with Type 1 diabetes earlier and more accurately would benefit the management of those patients.

Antigen Express’s technology allows for more potent and specific activation of CD4+ T helper cells, both after immunization and using blood cells outside the body. In Type 1 diabetes, also known as juvenile-onset diabetes, the cells become aberrantly activated to recognize proteins associated with cells involved in insulin secretion, leading to the cells’ destruction.